Heron Therapeutics, Inc. (HRTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Heron Therapeutics, Inc. (HRTX) is down 67.8% since the beginning of the year. At $0 per share, HRTX is trading 81.8% below its 52-week high of $2. Investors who bought $1,000 worth of HRTX shares 5 years ago would now be looking at an investment worth $27.

Heron Therapeutics, Inc. (HRTX) has returned -67.80% so far this year and -80.16% over the past 12 months. Over the last ten years, HRTX has returned -31.04% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.

Based on dividend-adjusted daily data since Aug 27, 1987, HRTX's average daily return is +0.05%, while the average monthly return is +0.56%. At this rate, an investment would double in approximately 10.3 years.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2023 with a return of +93.1%, while the worst month was Aug 2004 at -60.9%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 9 months.

On a daily basis, HRTX closed higher 42% of trading days. The best single day was May 29, 2015 with a return of +60.0%, while the worst single day was Aug 12, 2004 at -57.0%.

Heron Therapeutics, Inc. has an annualized alpha of 6.04%, beta of 0.79, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since August 27, 1987.

• This stock participated in 141.39% of S&P 500 Index downside but only 27.67% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HRTX ranks 4 for risk / return — in the bottom 4% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Heron Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Heron Therapeutics, Inc. was 99.97%, occurring on Jun 16, 2026. The portfolio has not yet recovered.

The current Heron Therapeutics, Inc. drawdown is 99.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Heron Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Heron Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.